Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1

Oncotarget

Volumn 4, Issue 11, 2013, Pages 1948-1962

  Francipane, Maria Giovanna ^a,b   Lagasse, Eric ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Istituto Mediterraneo per i Trapianti e Terapie (ISMETT) Ad Alta Specializzazione RIMED Foundation   (Italy)

Author keywords

Apoptosis; Cancer stem cells; Colorectal cancer; mTOR

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BECLIN 1; CD24 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; KI 67 ANTIGEN; KU 0063794; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NOTCH RECEPTOR; OXALIPLATIN; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; SERINE; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TEMSIROLIMUS; THREONINE; TORIN 1; UNCLASSIFIED DRUG; WYE 354;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER INHIBITION; CANCER STEM CELL; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CENTROSOME; CLONOGENESIS; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESISTANCE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; METASTATIC COLORECTAL CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; NAPHTHYRIDINES; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84890152601     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1310     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA: a cancer journal for clinicians. 2010; 60(5):277-300.
2. Foster KG and Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. The Journal of biological chemistry. 2010; 285(19):14071-14077.
3. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Current biology: CB. 2004; 14(14):1296-1302.
4. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL and Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular cell. 2006; 22(2):159-168.
5. Fingar DC, Salama S, Tsou C, Harlow E and Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes&development. 2002; 16(12):1472-1487.
6. Julien LA, Carriere A, Moreau J and Roux PP. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Molecular and cellular biology. 2010; 30(4):908-921.
7. Carlson CJ, White MF and Rondinone CM. Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation. Biochemical and biophysical research communications. 2004; 316(2):533-539.
8. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, Kubica N, Hoffman GR, Cantley LC, Gygi SP and Blenis J. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science. 2011; 332(6035):1322-1326.
9. Sarbassov DD, Guertin DA, Ali SM and Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307(5712):1098-1101.
10. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A and Hall MN. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nature cell biology. 2004; 6(11):1122-1128.
11. Garcia-Martinez JM and Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). The Biochemical journal. 2008; 416(3):375-385.
12. Zhou H, Luo Y and Huang S. Updates of mTOR inhibitors. Anti-cancer agents in medicinal chemistry. 2010; 10(7):571-581.
13. Aoki K, Tamai Y, Horiike S, Oshima M and Taketo MM. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice. Nature genetics. 2003; 35(4):323-330.
14. Fujishita T, Aoki K, Lane HA, Aoki M and Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(36):13544-13549.
15. Shao J, Evers BM and Sheng H. Roles of phosphatidylinositol 3'-kinase and mammalian target of rapamycin/p70 ribosomal protein S6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer research. 2004; 64(1):229-235.
16. Gulhati P, Cai Q, Li J, Liu J, Rychahou PG, Qiu S, Lee EY, Silva SR, Bowen KA, Gao T and Evers BM. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(23):7207-7216.
17. Roper J, Richardson MP, Wang WV, Richard LG, Chen W, Coffee EM, Sinnamon MJ, Lee L, Chen PC, Bronson RT, Martin ES and Hung KE. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PloS one. 2011; 6(9):e25132.
18. Blaser B, Waselle L, Dormond-Meuwly A, Dufour M, Roulin D, Demartines N and Dormond O. Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells. BMC cancer. 2012; 12:86.
19. Zhang Y and Zheng XF. mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle. 2012; 11(3):594-603.
20. O'Brien CA, Pollett A, Gallinger S and Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445(7123):106-110.
21. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445(7123):111-115.
22. Cai Z, Ke J, He X, Yuan R, Chen Y, Wu X, Wang L, Wang J, Lan P and Wu X. Significance of mTOR Signaling and Its Inhibitor Against Cancer Stem-Like Cells in Colorectal Cancer. Annals of surgical oncology. 2013.
23. Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz DB, Lewis DW, Gollin SM, Gamblin TC, Geller DA and Lagasse E. A stochastic model for cancer stem cell origin in metastatic colon cancer. Cancer research. 2008; 68(17):6932-6941.
24. Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, Xu MH, Chen GQ, Han ZG and Fang JY. mTOR signaling pathway is a target for the treatment of colorectal cancer. Annals of surgical oncology. 2009; 16(9):2617-2628.
25. Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, Giovannucci E, Fuchs CS and Ogino S. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer. 2011; 117(7):1399-1408.
26. Cybulski N and Hall MN. TOR complex 2: a signaling pathway of its own. Trends in biochemical sciences. 2009; 34(12):620-627.
27. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. The Journal of clinical investigation. 2008; 118(6):2111-2120.
28. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C and Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(24):10158-10163.
29. Visvader JE and Lindeman GJ. Mammary stem cells and mammopoiesis. Cancer research. 2006; 66(20):9798-9801.
30. Yan M. Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vascular cell. 2011; 3:17.
31. Wang Y, Srinivasan K, Siddiqui MR, George SP, Tomar A and Khurana S. A novel role for villin in intestinal epithelial cell survival and homeostasis. The Journal of biological chemistry. 2008; 283(14):9454-9464.
32. Asao T, Nakamura J, Shitara Y, Tsutsumi S, Mochiki E, Shimura T, Takenoshita S and Kuwano H. Loss of standard type of CD44 expression in invaded area as a good indicator of lymph-node metastasis in colorectal carcinoma. Diseases of the colon and rectum. 2000; 43(9):1250-1254; discussion 1254-1255.
33. Winter MJ, Nagelkerken B, Mertens AE, Rees-Bakker HA, Briaire-de Bruijn IH and Litvinov SV. Expression of Ep-CAM shifts the state of cadherin-mediated adhesions from strong to weak. Experimental cell research. 2003; 285(1):50-58.
34. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M and Gires O. Nuclear signalling by tumour-associated antigen EpCAM. Nature cell biology. 2009; 11(2):162-171.
35. Francipane MG, Chandler J and Lagasse E. Cancer Stem Cells: A Moving Target. Current pathobiology reports. 2013; 1(2):111-118.
36. Komori J, Boone L, DeWard A, Hoppo T and Lagasse E. The mouse lymph node as an ectopic transplantation site for multiple tissues. Nature biotechnology. 2012; 30(10):976-983.
37. Battelli C and Cho DC. mTOR inhibitors in renal cell carcinoma. Therapy. 2011; 8(4):359-367.
38. Castilho RM, Squarize CH, Chodosh LA, Williams BO and Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell stem cell. 2009; 5(3):279-289.
39. Easley CAt, Ben-Yehudah A, Redinger CJ, Oliver SL, Varum ST, Eisinger VM, Carlisle DL, Donovan PJ and Schatten GP. mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells. Cellular reprogramming. 2010; 12(3):263-273.
40. Tyler WA, Gangoli N, Gokina P, Kim HA, Covey M, Levison SW and Wood TL. Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009; 29(19):6367-6378.
41. Yang Z, Zhang L, Ma A, Liu L, Li J, Gu J and Liu Y. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PloS one. 2011; 6(12):e28405.
42. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer cell. 2009; 16(1):21-32.
43. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, Li S, Tsui C, Tie J, Desai J, Xu ZZ, Molloy P, Whitehall V, Leggett BA, Jones IT, McLaughlin S, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(12):3285-3296.
44. Francipane MG and Lagasse E. Genetic Instability and Epigenetic Diversity of Cancer: A Focus On Colorectal Cancer. In: "Cancer Targeted Drug Delivery: Elusive Dream" (YH Bae et al, eds) Springer 2013.
45. Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM and Gray NS. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. Journal of medicinal chemistry. 2010; 53(19):7146-7155.
46. Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, Gudkov AV and Antoch MP. New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53-/- mice by delaying carcinogenesis. Aging. 2012; 4(10):715-722.
47. Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, Blagosklonny MV and Gudkov AV. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. Aging. 2012; 4(10):709-714.
48. Liu Q, Wang J, Kang SA, Thoreen CC, Hur W, Ahmed T, Sabatini DM and Gray NS. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer. Journal of medicinal chemistry. 2011; 54(5):1473-1480.
49. Garrett JT, Chakrabarty A and Arteaga CL. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget. 2011; 2(12):1314-1321.
50. Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M and McCubrey JA. Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget. 2012; 3(4):371-394.